Decision Impact
|
|
Impact of a Commercial Reference Laboratory Test Recurrence Score on Decision Making in Early-Stage Breast Cancer
|
|
R Oratz, D Paul, AL Cohn, SM Sedlacek
|
|
J Oncol Pract
2007.3(4):182-186.
|
|
|
|
Does Oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
|
|
Juhi Asad, D.O.a,b, Allyson F. Jacobson, M.D.a,b, Alison Estabrook, M.D.a, Sharon Rosenbaum Smith, M.D.a, Susan K. Boolbol, M.D.b, Sheldon M. Feldman, M.D.b, Michael P. Osborne, M.D.b, Kwadwo Boachie-Adjei, M.Ph.c, Wendy Twardzik, R.P.A.-C.a, Paul I. Tartter, M.D.a,*
|
|
Am J Manag Care
2008
|
|
|
|
Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers
|
|
R Simon
|
|
J Clin Oncol
2005.23(29):7332-7341.
|
|
|
|
Development and Clinical Utility of a 21-Gene Recurrence Score Prognostic Assay in Patients with Early Breast Cancer Treated with Tamoxifen
|
|
S Paik
|
|
Oncologist
2007.12(6):631-635.
|
|
|
|
Low Recurrence Score by the Oncotype DX Breast Cancer Assay Rarely Results in Recommendation for or Administration of Chemotherapy: A Pooled Analysis
|
|
P Hall, S Skrypczak, G Palmer
|
|
Abstract # 2601: Poster Session
|
|
|
|
Prospective Multi-Center Study of the Impact of the 21-Gene Recurrence Score Assay on Patient Satisfaction, Anxiety and Decisional Conflict for Adjuvant Breast Cancer Treatment Selection
|
|
PB Mumby, SS Lo, J Norton, J Smerage, K Joseph, HK Chew, D Hayes, KS Albain
|
|
Abstract #1092: Poster Session
|
|
|
|
A Retrospective Analysis of the Impact of Oncotype DX Low Recurrence Score Results on Treatment Decisions in a Single Academic Breast Cancer Center
|
|
H Liang, AM Brufsky, BB Lembersky, P Rastogi, VG Vogel
|
|
Abstract #2061: Poster Session
|
|
|
|
Evaluation of Practice Patterns in the Treatment of Node-Negative, Hormone-Receptor Positive Breast Cancer Patients with the Use of the Oncotype DX Assay at the University of Pennsylvania
|
|
C Erb, KR Fox, M Patel, K Hook, A DeMichele, C Kaplan, S Domchek
|
|
Abstract #3082: Poster Session
|
|
|
|
Prospective Multi-Center Study of the Impact of the 21-Gene Recurrence Score (RS) Assay on Medical Oncologist (MO) and Patient (PT) Adjuvant Breast Cancer (BC) Treatment Selection
|
|
SS Lo, J Norton, PB Mumby, J Smerage, J Kash, HK Chew, D Hayes, A Epstein, KS Albain
|
|
Abstract #577: Poster Session
|
|
|
|
Impact of Oncotype DX® on Decision Making in Breast Cancer Clinical Practice
|
|
R Oratz, D Paul, A Cohn, S Sedlacek
|
|
Abstract #2049: Poster Session
|
|
|
|
Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
|
|
Eleftherios P. Mamounas,*Gong Tang, Bernard Fisher, Soonmyung Paik, Steven Shak, Joseph P. Costantino, Drew Watson, Charles E. Geyer Jr, D. Lawrence Wickerham, and Norman Wolmark
|
|
J Clin Oncol
2010
|
|
|
|
Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection.
|
|
Shelly S. Lo,*Patricia B. Mumby, John Norton, Karen Rychlik, Jeffrey Smerage, Joseph Kash, Helen K. Chew, Ellen R. Gaynor, Daniel F. Hayes, Andrew Epstein, and Kathy S. Albain
|
|
J Clin Oncol
2010
|
|
|